New York, New York--(Newsfile Corp. - February 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of agilon health, inc. (NYSE: AGL) between February 26, 2025 and August 4, 2025, both dates inclusive (the "Class Period"), of the important March 2, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.SO WHAT: If you purchased agilon securities during the Class Period you may be entitled to compensation without payment of any ou ...

New York, New York--(Newsfile Corp. - February 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ardent Health, Inc. (NYSE: ARDT) between July 18, 2024 and November 12, 2025, both dates inclusive (the "Class Period"), of the important March 9, 2026 lead plaintiff deadline.SO WHAT: If you purchased Ardent Health securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...

SAN FRANCISCO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is notifying investors in Ardent Health, Inc. (NYSE: ARDT) regarding the March 9, 2026, lead plaintiff deadline in a pending securities class action the company and certain of its top executives. CLICK HERE TO SUBMIT YOUR ARDT LOSSES The litigation focuses on the revelation in Nov. 2025 that Ardent alleged utilized a rigid 180-day cliff to reserve for uncollectible accounts – a process that the complaint alle ...

Achieved positive net income and earnings per share one year ahead of internal expectations, marking a significant maturity milestone for the public company. Realized a 7% improvement in clinician productivity during the second half of 2025 by optimizing scheduling processes and implementing a new cash incentive program. Successfully balanced net clinician growth with existing capacity utilization to drive higher visits per clinician and improve overall operating leverage. Enhanced patient acquisiti ...

McKesson Corporation (NYSE:MCK) is included among the Goldman Sachs Dividend Stocks: Top 14 Stock Picks. Barclays Boosts McKesson (MCK) Price Target, Says Shares Likely to Stay in Favor On February 18, Barclays raised its price objective on McKesson Corporation (NYSE:MCK) to $1,050 from $960. The firm reiterated an Overweight rating on the shares. Analysts said the stock is expected to “remain in favor” as investors look for “pockets of safety within healthcare.” At the same time, the firm noted that McK ...

Wall Street analysts expect Progyny (PGNY) to post quarterly earnings of $0.38 per share in its upcoming report, which indicates a year-over-year decline of 9.5%. Revenues are expected to be $303.93 million, up 1.8% from the year-ago quarter.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Before a company announces its earnings, it is essentia ...

Equity markets appear poised for their next leg of expansion after nine months of tight consolidation, with the Nifty trading in a narrow 5–6 per cent band amid global uncertainties and earnings recalibrations. According to PL Capital’s latest India Strategy report, the index has weathered a 9–9.5 per cent moderation in FY26–27 EPS estimates, yet underlying corporate performance remains resilient.The base case assumes the Nifty index with a 12-month target of 27,958. In a bullish scenario, a 20x multiple im ...

Core Insights - Evolent Health reported a revenue of $468.72 million for the quarter ended December 2025, reflecting a year-over-year decline of 27.5% [1] - The company's EPS for the same period was $0.08, compared to -$0.02 a year ago, indicating a positive turnaround [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $469.22 million, resulting in a surprise of -0.11%, while the EPS exceeded expectations by 28% [1] Financial Performance - Evolent Health's shares have decreased by 25.3% over the past month, contrasting with the Zacks S&P 500 composite's decline of only 1% [3] - The company currently holds a Zacks Rank of 3 (Hold), suggesting it may perform in line with the broader market in the near term [3] Key Metrics - Average PMPM Fees / Revenue per Case for Performance Suite was $13.87, slightly below the estimated $14.14 [4] - Average Lives on Platform for Cases reached 14 thousand, slightly above the estimated 13.86 thousand [4] - Total Revenue by product type for Performance Suite was $269.46 million, which is a 41% decline compared to the year-ago quarter [4] - Total Revenue by product type for Specialty Technology and Services Suite was $95.74 million, showing a year-over-year increase of 16.3% [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ardent Health, Inc. due to allegations of violations of federal securities laws related to misleading statements and undisclosed information regarding accounts receivable and revenue recognition [2][4]. Group 1: Allegations and Financial Impact - The complaint alleges that Ardent Health and its executives made false statements regarding the company's accounts receivable and the processes used to determine their collectability [4]. - On November 12, 2025, Ardent Health disclosed a $43 million decrease in third quarter 2025 revenue, attributed to revised determinations of accounts receivable collectability following a transition to a new revenue accounting system [4]. - The new accounting system, Kodiak RCA net revenue platform, allowed for more precise determination of accounts receivable collectability, leading to earlier recognition of reserves compared to the previous framework [4]. - Ardent Health also reduced its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $625 million to $530 million - $555 million, citing persistent industry-wide cost pressures [4]. - Following this announcement, Ardent Health's stock price fell by nearly 34%, from $14.05 to $9.30 per share on November 13, 2025, on unusually heavy trading volume [4]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased or acquired securities in Ardent between July 18, 2024, and November 12, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][2]. - There is an April 21, 2026, deadline for investors to seek the role of lead plaintiff in the federal securities class action filed against Ardent [2][5]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought by the class, who will oversee the litigation on behalf of the class members [5].

Evolent Health (NYSE:EVH) Q4 2025 Earnings call February 24, 2026 05:00 PM ET Company ParticipantsDavid Larsen - Managing DirectorJailendra Singh - Managing DirectorJared Haase - Senior Research AssociateJeff Garro - Managing DirectorJohn Stansel - Equity Research AssociateKevin Caliendo - Managing DirectorMario Ramos - CFORichard Close - Managing DirectorRyan Halstead - Managing DirectorSeth Blackley - CEONone - Company RepresentativeConference Call ParticipantsDaniel Grosslight - Senior Research AnalystJe ...